Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A Device for Phage Capture and Release

Project description

Unleashing the power of bacteriophages

Bacteriophages – viruses that selectively kill bacteria – are promising tools for combating antibiotic resistance and advancing biotechnology. Their wider use is held back by slow, labour-intensive and largely unreliable methods for identifying suitable phages and assembling treatment ‘cocktails’. Purification after production in bacterial hosts is another barrier. The ERC-funded PhageTRAP project aims to establish proof of concept for a modular platform that selectively captures and releases phages using synthetic molecular motifs anchored to a solid support. Combining synthetic chemistry and microbiology, the platform will enable high-throughput phage screening, therapy assembly and production of clinically safe preparations. If successful, PhageTRAP could be a step change, supporting faster, safer and more reliable development of phage-based therapies and industrial biotechnologies.

Objective

Bacteriophages are viruses that specifically infect bacteria and offer powerful solutions for combating antibiotic resistance, advancing industrial biotechnology, and enabling fundamental research. Major challenges hinder the broader use of phages in therapy and biotechnology. Identifying suitable phages and assembling complementary cocktails remains slow, labor-intensive, and largely unsystematic. Purification is equally problematic, as production in bacterial hosts introduces endotoxins, DNA, and other contaminants that are difficult to remove with current methods, which are inefficient, slow, and not scalable. Together, these obstacles represent critical bottlenecks and highlight the urgent need for reliable, rapid, and safe phage capture technologies.
The PhageTRAP project aims to establish the proof of concept for a modular platform that can selectively capture and release phages using synthetic motifs tethered to a solid support. Different motifs will target Gram-positive pathogens, while other motifs will serve as examples for the customizable capture of Gram-negative pathogens. The platform will be validated with species clinically relevant for phage therapy and tested on phages recovered from environmental sources. By combining synthetic chemistry and microbiology, this proof-of-concept project will demonstrate a highly innovative, scalable, and safe approach to phage capture, enabling high-throughput screening, assembly of complementary phage cocktails, and production of therapeutic-grade preparations. The resulting platform has strong translational potential, clear industrial and clinical applications, and opportunities for commercialization and intellectual property development. Ultimately, PhageTRAP could become a disruptive technology for advancing phage-based therapeutics, transforming them into faster, safer, and more reliable tools for medicine and biotechnology.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITAT WIEN
Net EU contribution
€ 150 000,00
Address
UNIVERSITATSRING 1
1010 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)